#1088-101 Effect of a nutrient mixture on matrix metalloproteinase-9 dimers in various human cancer cell lines

M.W. Roomi^{*}, N.W. Roomi, A. Niedzwiecki and M. Rath Dr. Rath Research Institute, 1260 Memorex Drive, Santa Clara, CA 95050

Introduction

Strong clinical and experimental evidence demonstrates association of elevated levels of matrix metalloproteinase MMP-9 with cancer progression, metastasis and shortened patient survival, as it plays a key role in tumor cell invasion and metastasis by digesting the basement membrane and ECM components. MMP-9 is secreted in both the monomeric and dimeric form. Though there is little research on MMP-9 dimers, some studies have shown the dimer to be associated with more aggressive tumor progression.

Objective

Our objective was to study the relative secretion patterns of MMP-9 monomer and dimer by a variety of cancer cell lines and the effect of a nutrient mixture (NM) containing lysine, proline, ascorbic acid and green tea extract on MMP-9 secretion.

Materials and Methods

1. The cancer cell lines were grown in their respective media, supplemented with 10% FBS, penicillin (100 units/ml), and streptomycin (100 µg/ml) in 24well tissue culture plates.

2. At near confluence, the cells were treated with NM at 0,10, 50, 100, 500 and 1000 µg/ml. Parallel sets of cultures were treated with PMA (100 ng/ml) for induction of MMP-9.

3. Cell MMP-9 monomer and dimer secretion was assayed by gelatinase zymography.

Composition of NM

Vitamin C (as ascorbic acid and as	
Mg, Ca and palmitate ascorbate)	700 mg
L-Lysine	1000 mg
L-Proline	750 mg
L-Arginine	500 mg
N-Acetyl Cysteine	200 mg
Standardized Green Tea Extract	
(80% polyphenol)	1000 mg
Selenium	30 µg
Copper	2 mg
Manganese	1 mg

Humar

Breast MD MCF Colo Cervica Hela Dol Uterine SK-ME MES Prostat Du-PC-Testicul NT Lung & Lung MS Gastroi SK-Hep M1A HCT Urologia T-24 RCC Head & FaD Tong FAH Glioblas A-17 T-98 Neu Sarcom Oste SK-E Rhab Oste Sarcom Fibro Chon Lipos Sync Hemato HL-6 Raji Melanc A-20

Results

1. MMP-9 monomer and dimer secretion patterns of cancer cells fell into different categories. See Table 1.

Table 1 - Human cancer cell lines expressing MMP-9 and dimer without and with PMA stimulation

na with PiviA stimu	allon			
n Cancer Cell Line		Expression MA With PMA	Dimer Formation Without PMA With PMA	
Cancer				
A-MB-231	-	+	-	++
F-7	-	+	-	++
o-824	+	++	+	++
al Cancer				
a	-	++	-	++
Tc 2 4510	+	++	+	++
e Cancer				
-UT-1	_	++	_	++
S-SA	_	+		
S-SA/DX5	-	+	-	-
		т	-	-
te Cancer				
145	-	+	-	-
3	+	+	-	-
lar				
ER-2	-	+	-	-
Mesothelioma				
g A-549	-	+	-	+
TO-211H	+	++	-	-
intestinal				
Hep-1 (HCC)	+	++	+	++
oG2 (HCC)	-	+	_	_
A-Pa-Ca-2 (pancreas)	+	++		_
-116 (colon)	+	+		_
ical	T	т	-	-
(bladder)	-	+	<u> </u>	-
786-0 (renal)	+	++	+	++
& Neck				
U	-	++	-	-
jue	+	++	-	++
NSCC (OHSU-973)	+	++	-	-
stoma				
72	-	+	-	-
3	-	+	-	-
18	-	+	-	-
iroblastoma	_	+	_	-
nas-Pediatric				
eosarcoma MNNG-HOS	_	+	-	<u>_</u>
ES-1	_	+	_	
	-	-	-	-
bdomhyosarcoma	+	++	-	++
eosarcoma U-2OS	+	+	-	++
nas-Adult				
osarcoma HT-1080	+	++	-	++
ndrosarcoma	+	++	-	++
sarcoma	+	++	-	++
ovial sarcoma	+	++	-	-
ological				
50 U	-	+	-	-
	+	++	-	-
oma				
158	_	++	_	++

2. We observed no MMP-9 dimer in prostate DU-145 and PC-3, pancreatic MIA-Pa-Ca2, colon HCT-116, bladder T-24, head and neck FaDu, glioblastoma A-172, T-98 and LN-18 and leukemia HL-60, Jurkat, and Raji cell lines. (No figures shown.)

3. MMP-dimer secretion only with PMA induction was seen in breast MCF-7 and MDA-MB-231, uterine SK-UT-1, lung A-549, tongue SC-25, melanoma A2058, osteosarcoma U-2OS, rhabdomyosarcoma, fibrosarcoma HT-1080, chondrosarcoma SW-1353 and liposarcoma SW-872. Figures 1-4 show MMP-9 patterns for representative cell lines breast MCF-7 (1), lung A-549 (2), osteosarcoma U-2OS (3), chondrosarcoma SW-1353 (4). NM inhibited secretion of both MMP-9 monomer and dimer in all cell lines in a dose-dependent manner.

MMP-9 dimer MMP-9

MMP-9 dimer MMP-9

MMP-9 dimer

MMP-9

3-7 100 ng/ml PMA and 50, 100, 250, 500 and 1000 µg/ml NM

MMP-9 dir

MMP-9

1000 µg/ml NM

4. Cervical Hela and DoTc-2 4510, renal 786-0, hepatocelluar carcinoma (HCC) SK-Hep-1 and uterine SK-UT-1 cell lines exhibited MMP-9 dimer without PMA treatment and increased secretion with PMA treatment. Figures 5-7 show MMP-9 patterns for representative cell lines cervical DoTc 2 4510 (5), HCC SK-Hep-1 (6) and uterine SK-UT-1 (7). NM inhibited secretion of both MMP-9 monomer and dimer in all cell lines in a dose-dependent manner.






Figure 1 - Effect of NM on PMA-treated breast MCF-7 cell MMP-9 monomer and dimer secretion dimer 13% of MMP-9











Figure 3 - Effect of NM on PMA-treated osteosarcoma U-2OS cell MMP-9 monomer and dimer secretion







50 100 250 500 1000 NM in µg/ml

Figure 4- Effect of NM on PMA-treated chondrosarcoma SW-1353 cell MMP-9 monomer and dimer secretion





MMP-9 activ



5. Sarcomas had the highest levels of MMP-9 monomer and dimer with and without PMA among these cancer cell lines. Cervical, uterine, and male breast cancer cell lines showed the next highest levels of MMP-9, followed by breast cancer cell lines. Melanoma, renal, lung, head and neck and HCC showed lower levels and prostate, glioblastoma, bladder and leukemia cell lines the lowest. NM showed dose-dependent inhibition of MMP-9 monomer and dimer in all cell lines tested.

Conclusions In conclusion, high MMP-9 and dimer secretion levels correlated with the most aggressive cancer cell lines. NM was effective in inhibiting MMP-9 and dimer secretion in all cell lines tested, suggesting its therapeutic potential as an antimetastatic agent.

